SCHEMBL10169715

SCHEMBL10169715

CC(C)CN1CC(Oc2ccc(-c3c(-c4ccccc4Cl)noc3-c3ccc(O)cc3)cc2)C1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.39
HSP90AB1 P08238 1/20 0.39
PDK1 Q15118 1/20 0.39
S1PR1 P21453 4/20 0.39
S1PR3 Q99500 3/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
ESR1 P03372 2/20 0.36
ALOX5 P09917 1/20 0.35
ALOX5AP P20292 1/20 0.35
PPARD Q03181 3/20 0.35
NR1H4 Q96RI1 3/20 0.35
GRIN1 Q05586 6/20 0.35
GRIN2B Q13224 6/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9955834 0.99 HSP90AA1 (0.39) HSP90AA1HSP90AB1PDK1S1PR1S1PR3
SCHEMBL9956414 0.89 ESR1 (0.46) S1PR1S1PR3PTGS1PTGS2ESR1
Hydrochloric Acid SCHEMBL9955635 0.88 ESR1 (0.45) S1PR1S1PR3PTGS1PTGS2ESR1
SCHEMBL10169930 0.87 PTGS1 (0.37) HSP90AA1S1PR1S1PR3PTGS1PTGS2
SCHEMBL10169926 0.87 ESR1 (0.41) S1PR1S1PR3PTGS1PTGS2ESR1
SCHEMBL10169719 0.87 ESR1 (0.40) HSP90AA1HSP90AB1PDK1S1PR1S1PR3
Hydrochloric Acid SCHEMBL9955889 0.86 ESR1 (0.40) S1PR1S1PR3PTGS1PTGS2ESR1
Hydrochloric Acid SCHEMBL9956577 0.86 PTGS1 (0.36) HSP90AA1S1PR1S1PR3PTGS1PTGS2
Hydrochloric Acid SCHEMBL9957111 0.86 ESR1 (0.40) HSP90AA1HSP90AB1PDK1S1PR1S1PR3
SCHEMBL10169722 0.85 ESR1 (0.49) ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540361-B2 N-substituted azetidine derivatives MERCK SHARP & DOHME B.V. (NL) 2017-01-10 US disclosed
US-9540361-B2 N-substituted azetidine derivatives MERCK SHARP & DOHME B.V. (NL) 2017-01-10 US disclosed
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2016-05-12 US disclosed
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2016-05-12 US disclosed
WO-2012084711-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MSD OSS B.V. (NL) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES ESR2, ESR1, GPER1 HSP90AA1 2909/4885HSP90AB1 2545/4885PDK1 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.